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ABSTRACT
The incidence of idiopathic pulmonary fibrosis is on the rise and existing treatments have failed to
halt or reverse disease progression. Mesenchymal stromal cells (MSCs) have potent cytoprotective
effects, can promote tissue repair, and have demonstrated efficacy in a range of fibrotic lung dis-
eases; however, the exactmechanisms of action remain to be elucidated. Chemical antagonists and
short hairpin RNA knockdownwere used to identify themechanisms of action used byMSCs in pro-
motingwound healing, proliferation, and inhibiting apoptosis. Using the bleomycin induced fibrosis
model, the protective effects of early or late MSC administration were examined. The role for he-
patocyte growth factor (HGF) in MSC protection against bleomycin lung injury was examined using
HGF knockdown MSC. Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling assay
was performed on ex vivo lung sections to examine the effects of MSC on apoptosis. MSC condi-
tioned media (CM) enhanced wound closure and inhibited apoptosis of pulmonary cells in vitro.
HGF was required for MSC CM enhancement of epithelial cell proliferation and inhibition of apo-
ptosis. In contrast,MSC required COX-2 for CM to inhibit fibroblast proliferation. In amurinemodel,
early administration of MSC protected against bleomycin induced lung fibrosis and correlated with
reduced levels of the proinflammatory cytokine interleukin-1b, reduced levels of apoptosis, and
significantly increased levels of HGF. These protective effectswere in partmediated byMSC derived
HGFasHGFknockdownMSCwere unable toprotect against fibrosis in vivo. These findings delineate
the mechanisms of MSC protection in a preclinical model of fibrotic lung disease. STEM CELLS
TRANSLATIONAL MEDICINE 2016;5:1307–1318
SIGNIFICANCE
The mechanisms used by mesenchymal stromal cells (MSCs) in mediating protective effects in
chronic models of lung disease are not understood and remain to be elucidated. These findings
from in vitro studies highlight an important role for the MSC-derived soluble factors hepatocyte
growth factor (HGF) and prostaglandin E2 in promoting wound healing and inhibiting apoptosis.
Furthermore, this study translates these findings demonstrating an important role for HGF in
the protective effects mediated by MSC in vivo in the bleomycin model. These findings support
a targeted approach to enhancing MSC therapy for fibrotic disease and highlight the importance
of timing of MSC therapy.
INTRODUCTION
Pulmonary fibrosis is a chronic disease associated
with remodeling of the lung architecture and
excessive deposition of activated fibroblasts in
parenchymal tissue. This leads to formation of
scar tissue, which becomes a permanent feature
once formed. Fibrosis can arise from chronic
stimuli; however, many cases are classified as
idiopathic. The disease is life threatening with
limited treatment options, often necessitating
organ transplant. The exact cause of pulmonary
fibrosis is as yet unknown but ultimately results
from aberrant wound healing.
Normal wound healing can be divided into
three principle stages: inflammation, proliferation,
and repair. In the case of pulmonary fibrosis, the
initial injury can come in the form of a chemical,
biological, or physical insult, and more often
than not, the stimulus is chronic [1]. Irrespective
of the source, damage to the lung epithelium re-
sults in exposure of endothelium and basement
membrane proteins leading to the recruitment
and activation of innate and adaptive immune
cells [2]. The final phase of wound healing, re-
pair, is a delicate balance between the degrada-
tion of scar tissue and the generation of new
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epithelium and, depending on the type ofwound, can take years
[3]. In vivo studies on fibrosis have relied predominantly on the
bleomycin induced animal model of pulmonary fibrosis. The
damage in this model is caused by bleomycin-induced reactive
oxygen species and cleavage of DNA strands [4].
Mesenchymal stromal (stem) cells (MSCs) can inhibit inflam-
mation and regulate immune responses in vitro and in vivo [5–8].
In addition, MSCs can differentiate into a number of lineages in-
cluding bone, fat, and cartilage. However, it is becoming apparent
that theprotective effects associatedwithMSC therapy are based
less on in situ differentiation abilities and more on paracrine or
trophic factors [9]. MSCs can home to sites of injury and induce
repair through the release of trophic factors, such as cytokines
[10]. The importance of chemotaxis, engraftment, [11, 12] and cy-
tokine production [13–15] in MSC protection against bleomycin
induced pathology has been demonstrated by a number of pre-
clinical studies [12–13, 14–16]; however,much remains unknown
about how MSCs function. MSCs are known to mediate potent
anti-inflammatory effects in the context of lung inflammation.
For example, MSCs can promote the polarization of anti-
inflammatory M2 macrophages [16] and regulatory T cells [5,
17], and they directly inhibit effector T cells [18]. Recently, alloge-
neic human MSCs have been shown to be safe in a clinical trial in
chronic obstructive pulmonary disease with an early significant
decrease in circulating levels of C-reactive protein [19]. The in-
creasing use of allogeneic MSCs instead of autologous MSCs is
an important factor in a broadly applicable off-the-shelf therapy
and supports the use of allogeneic MSCs in preclinical studies
where appropriate.
In the setting of bleomycin-induced fibrosis, the major cells
involved are fibroblasts and epithelial cells. The effects of MSCs
and MSC-derived trophic factors on these cell types in wound
healing, apoptosis, and fibrosis are not understood.
Hepatocyte growth factor (HGF) is paracrine growth factor
involved in growth, proliferation, and migration of epithelial and
endothelial cells, its primary function being tissue repair [20].
HGF treatment has been shown to have a positive effect in the
bleomycin model, demonstrating a reduction in pathology and
collagen deposition following immediate and delayed adminis-
tration [21], as well as encouraging the proliferation of epithelial
cells both in vitro and in vivo [22].MSCs can be induced to secrete
HGF following inflammatory stimulation [22, 23].
This study aimed to identify the mechanisms of action of al-
logeneicMSC protective effects on pulmonary cells in vitro, influ-
encing the proliferation andmigration of fibroblasts and alveolar
epithelial cells. These effectsweremediated by soluble factors re-
leased by MSCs. In particular, MSC secretion of HGF played a key
role in MSC promotion of wound healing and prevention of apo-
ptosis. Using short hairpin RNA (shRNA) technology, the rele-
vance of HGF secretion by MSC in support of wound healing
was demonstrated, supporting a role for allogeneic MSC as a cell
therapy in the early stages of pulmonary fibrosis.
MATERIALS AND METHODS
Animals
Six- to 8-week-old female BALB/c, or C57BL/6mice (Envigo, Cam-
bridge, U.K., http://www.envigo.com.), were used for cell based
experiments under the guidelines of the Irish Department of
Health and the approval of the research ethics committee of
Maynooth University. Mice were maintained according to the
regulations of the IrishDepartment ofHealth and the institutional
researchethics committee atMaynoothUniversity. C57BL/6mice
were chosen at random, weighed, and administered 4 U/kg of
bleomycin by intranasal instillation. The mice were lightly anes-
thetized with gaseous isofluorane, and 20 ml of bleomycin diluted
in phosphate-buffered saline (PBS) was administered to the nostrils
allowing the solution to be inhaled into the lungs. Control groups
weregiven20ml of PBS. Allogeneic BALB/cMSC (53 104/g)were
administered by intravenous injection to the tail vein using a
27-gauge needle and a 1-ml syringe either 6–8 hours after bleo-
mycin administration or 9 days later, and PBS was injected as a
negative control.
Histopathology
On day 28, lungs were harvested, fixed, and paraffin embedded
followed by sectioning and staining with hematoxylin and eosin
(H&E) (Sigma-Aldrich, St. Louis, MO, https://www.sigmaaldrich.
com) and Masson’s trichrome stain (Sigma-Aldrich). For H&E
staining tissue sections were stained in Harris hematoxylin solu-
tion and followed by counter staining with eosin. For Masson’s
trichrome stain, tissue was stained with Harris hematoxylin solu-
tion (nuclei), scarlet-acid fuchsin (muscle), and aniline blue (con-
nective tissue). Slides were then mounted with DPX Mountant
(Sigma-Aldrich) and airway pathology was examined in a blinded
fashion under a light microscope. At least five fields of view were
examined in five sections from five different mice per group.
Blinded analysis was then verified by two other researchers. A
semiquantitative scoring system was used to assess collagen de-
position and changes in lung architecture [23].
Isolation and Characterization of Bone Marrow-
Derived MSCs
Murine MSCs were isolated from the bone marrow of BALB/c
mice as previously described [5]. Briefly, following the isolation
of bone marrow, MSCs were cultured in complete Roswell Park
Memorial Institute (RPMI), supplemented with 10% (vol/vol)
heat-inactivated fetal bovine serum (FBS) (Gibco, Thermo Fisher
Scientific, Minneapolis, MN, https://www.thermofisher.com),
10% (vol/vol) equine serum (HyClone Laboratories, GEHealthcare
Life Sciences, Logan, UT, https://promo.gelifesciences.com/gl/
hyclone), 1% (vol/vol) penicillin/streptomycin (Gibco), and 1%
(vol/vol) L-glutamine (Gibco) for 28 days, replacingwith freshme-
dia every 3–4 days. At passage 2, MSCs were expanded in com-
plete a-minimum essential medium (CEM) supplemented with
10% (vol/vol) heat-inactivated FBS, 10% (vol/vol) equine se-
rum, 1% (vol/vol) penicillin/streptomycin, and 1% (vol/vol)
L-glutamine. MSCs were analyzed for the expression of a variety
of fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated surface markers including Sca-1, major histocom-
patibility complex (MHC) class I, MHC class II, CD11b, CD11c,
CD34, CD44, CD45, CD80, CD86, CD90, CD105, CD106, and
CD117 (eBioscience, Hatfield, U.K., http://www.ebioscience.
com) by flow cytometry (BD FACSCalibur and CellQuest software,
BD Biosciences, San Jose, CA, http://www.bdbiosciences.com) at
every passage. The differentiation capacity of MSCs following the
addition of differentiation media [5] into osteocytes, adipocytes,
and chondrocyteswere analyzed at every passage as previously de-
scribed. MSCs used in these studies expressed MHC class I, Sca-1,
CD44, and CD106 and differentiated into all three lineages
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mentioned above. The ability of MSCs to suppress allogeneic and
mitogen-driven proliferation was also assessed at each passage.
MSCs were used between passages 3 and 10.
Isolation and Characterization of Primary
Lung Fibroblasts
Primary lung fibroblastswere isolated from female C57BL/6mice.
The lungs were washed, digested using trypsin (Gibco), and diced
before incubation with DNase I solution (Sigma-Aldrich). The cell
suspensionwas centrifuged and resuspended in DNase II solution
(Sigma-Aldrich), followed by centrifugation and resuspension
in M199:Hams/F12 supplemented with 1% (vol/vol) penicillin/
streptomycin and 1% (vol/vol) L-glutamine. The cell suspension
was seeded into a 10-cmnontissue gradepetri dish and incubated
for1hourat 37°C,duringwhich time fibroblasts andmacrophages
adhered to the surface of the petri dish. Nonadherent cells were
removed and the adherent cells were allowed to reach con-
fluence in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich) supplemented with 10% (vol/vol) heat
inactivated FBS, 1% (vol/vol) penicillin/streptomycin, 1% (vol/vol)
L-glutamine, 1 ng/ml b-FGF (Peprotech, London, United Kingdom,
https://www.peprotech.com). Fibroblasts were isolated from
macrophages through selective passagingwith 2-minute trypsin
washes. At passage 2, the cells were characterized and stocks
frozen in liquid nitrogen. Primary fibroblastswere used in exper-
iments up to passage 5.
Short Hairpin RNA
Five HGF shRNA plasmids were expressed in the lentiviral vector
pGIPZ (Open Biosystems, GE Healthcare Life Sciences, http://
dharmacon.gelifesciences.com/about-us/about open biosys-
tems). HGF plasmids were transfected into HEK293T cells along
with the packaging plasmid trans-lentiviral packaging mix (Open
Biosystems) using Gene Juice (Merck Millipore, Darmstadt, Ger-
many, http://www.merckmillipore.com). HEK293T cellswere cul-
tured in high-glucose DMEM (Sigma-Aldrich) supplemented with
10% (vol/vol) heat inactivated FBS, 1% (vol/vol) penicillin/
streptomycin, and 1% (vol/vol) L-glutamine, and during transfec-
tion theywere cultured in serum-free DMEMwithout antibiotics.
After 24-hour transfection, they were cultured in medium con-
taining 30% FBS. Forty-eight hours after transfection, the super-
natant containing theHGF shRNA lentiviruswas collected. BALB/c
MSCs were transduced with the viral medium for 72 hours fol-
lowed by positive selection using 4mg/ml puromycin. Expression
and production of HGF were examined by real-time polymerase
chain reaction (PCR) and enzyme-linked immunosorbent assay
(R&D Systems, Minneapolis, MN, https://www.rndsystems.com)
according to themanufacturer’s instructions to ensure stable knock-
down following subcloning.
Generation of MSC-Conditioned Medium
MSCs (1 3 105 cells per 2 ml) were seeded in normal CEM and
allowed to adhere for 6 hours. MSCs were washed with PBS
and LA4, or fibroblast media was added. LA4medium; Dulbecco’s
modified Eagle’s medium nutrient mixture F12 (DMEM F12)
(Sigma-Aldrich) supplemented with 10% (vol/vol) heat inacti-
vated FBS, 1% (vol/vol) penicillin/streptomycin, and 1% (vol/vol)
L-glutamine. Fibroblastmedium; as described earlier. The condi-
tioned media (CM) were collected after 24 hours and concen-
trated using Amicon Ultra Centrifugal filters (Sigma-Aldrich).
The resulting CM -20ml concentrate derived from 13 105MSCs
during a 24-hour period was then added to the medium in the as-
says described later.
Coculture Experiments:MSCs, Fibroblasts, and LA4 Cells
Scratch Assay
The base of a six-well tissue culture plate (Sarstedt, Wexford, Ire-
land, https://www.sarstedt.com) was scored with three parallel
lines using a safety blade. Fibroblast or LA4 (lung alveolar epithe-
lial cells) cellswere seeded at a concentration of 13 105 cells per
well and allowed to form a confluent monolayer overnight in
fibroblast or LA4 medium. Using a P200 pipette tip (Sarstedt),
a line was scratched down the center of the well perpendicular
to the three lines on the base of the plate. The wells were
washed with warm PBS to remove floating cells, and fresh me-
diumwas added to all the wells. CM collected fromMSC seeded
in the appropriatemedia were concentrated using Amicon Ultra
Centrifugal filters, and the resulting protein-enriched fraction
(20 ml) was added to designated wells. The width of the scratch
was measured using Photoshop (Adobe, San Jose, CA, https://
www.adobe.com) from images taken using an inverted light mi-
croscope, and the lines scored on the bottom of the wells were
used as an alignment guide. The wells were observed daily. Once
the first well showed a full closure of the scratch, cells were fixed
with ice coldmethanol for 5minutes andwere stainedwith crystal
violet for 10minutes. The width of the closure wasmeasured in all
cultures from the same position and the results were graphed as a
percentage of closure when compared with the positive control.
Proliferation Assay
The confluent monolayer of LA4 or fibroblast cells was scratched
with a P1000 pipette tip and washed with PBS to remove de-
tached cells. Media collected from MSC (conditioned media)
was added to the designatedwells. CEMwas added to the control
wells. Tritiated thymidine (3H-thymidine) (Amersham Biosci-
ences, GE Life Sciences) at 0.5 mCi/ml was added to each well
and incubated at 37°C 5% carbon dioxide. Cultures were har-
vested after 3 days by removing the media and washing each
well three times with PBS. The cells were lysed using 500 ml of
1% sodium dodecyl sulfate (Sigma-Aldrich) and the lysate was
transferred to 3-ml plastic counting tubes. Two milliliters of
b-scintillation fluid (UltmaGold, Wallace-PerkinElmer, Waltham,
MA, http://www.perkinelmer.com) was added to each tube, vor-
texed, and placed in a 24-well cassette for reading. 3H-Thymidine
incorporation was quantified by a b-scintillation counter (1450
Microbeta Liquid Scintillation Counter; Wallace-PerkinElmer) and
results were expressed in counts per minute.
Apoptosis Assay
Apoptosiswas induced in LA4cells byadditionof cisplatinat4mg/ml
and incubated for 24 hours. MSC CM or control media were
added to test wells. Conditionedmedia were collected from non-
transduced MSCs, HGF knockdown MSCs, and nonsilencing con-
trolMSCs andwere addedwith cisplatin to the appropriate wells.
After 24 hours, apoptosis was measured by double staining of
annexin V and propidium iodide (PI) (eBioscience) and analyzed
by flow cytometry. The percentage of early apoptotic cells (lower
right quadrant annexin V+ PI–) was determined and graphed for
comparison.
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Myofibroblast Differentiation Assay
Fibroblastswere cultured at 23 105 cells perwell of a six-well plate.
The cells were stimulated with 50 ng/ml of recombinant mouse
TGF-b1 (R&DSystems),with the controlwell receiving no stimulant.
MSC CM was added to a further well containing TGF-b1 and was
cultured for 24 hours. The cells were collected in TRIzol Reagent
(Thermo Fisher) and were examined for expression of mouse a
smooth muscle actin (a-SMA) by quantitative real-time PCR.
Reverse Transcription-PCR and Real-Time PCR Analysis
Reverse transcription (RT)-PCR analysis was used to determine
the mRNA expression levels of mouse aggrecan and collagen
IIA in differentiated MSCs and HGF knockdown MSC. Real-time
PCR was used to determine the mRNA expression of a-SMA in
resting and stimulated fibroblasts andexpressionofmouse tumor
necrosis factor a (TNF-a), interleukin-1b (IL-1b), HGF, and TGF-b
in lungs tissue taken from the bleomycin model. TRI Reagent
(Thermo Fisher) was used to isolate total RNA and samples were
reverse transcribed to cDNA using a Tetro cDNA synthesis kit
(Biloine, Taunton,MA, http://www.bioline.com). RT-PCR analysis
was performed using a MyTaq DNA polymerase kit (Bioline).
Real-time PCR analysis was performed using SYBR Green reagent
(Sigma-Aldrich) and specific primers were used to determine
gene expression. The following PCR predesigned primers (Sigma-
Aldrich) were used: a-SMA: 59-39 CATCTTTCATTGGGATGGAG and
39-59 TTAGCATAGAGATCCTTCCTG; TNF-a: 59-39GGATGAGAAGTTCC-
CAAAT and 39-59 TGAGAAGATGATCTGAGTG; IL-1b: 59-39 GGATGAT-
GATGATAACCTGC and 39-59 CATGGAGAATATCACTTGTTGG; HGF:
59-39 CAAATGCAAGGACCTTAGA and 39-59 CTTCTTTTGGA-
TAAGTTGCC; TGF-b: 59-39 GGATACCAACTATTGCTTCAG and
39-59 TGTCCAGGCTCCAAATATAG. Glyceraldehyde-3-phosphate
dehydrogenase expression was used as a housekeeping gene us-
ing the following primers: 59-39 GCACAGTCAAGGCCGAGAAT and
39-59 GCCTTCTCCATGGTGGTGAA.
Statistics
Statistical analysis was performed using GraphPad Prism soft-
ware (GraphPad, San Diego, CA, http://www.graphpad.com/
company). The Student’s paired t test was used when statistical
analysis was required between two experimental groups. One-
way analysis of variance was used to test for statistical signifi-
cance of differences when multiple experimental groups were
Figure 1. MSC CM enhances wound closure of murine pulmonary cells in vitro. (A): Representative images (magnification 3 100) and (B):
Quantification of scratch assay examining the migration of primary murine lung fibroblasts in the presence or absence of MSC CM for
0 and 3 days. Representative images (magnification3 100) (C) and quantification (D) of scratch assay examining migration of murine alveolar
epithelial cells (LA4) in thepresenceofMSCCMat time0andafter 3days. Images are representativeof threeexperiments andbar graphdata are
presented asmean6 standard error of themeanof n =3. pp, p, .01; ppp,p, .001. Abbreviations: CM, conditionedmedia;MSC,mesenchymal
stromal cell.
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compared. Data are presented as the mean6 the standard error
of themean (SEM). p values of p, .05, p, .01, or p, .001 were
considered statistically significant.
RESULTS
MSC-Conditioned Media Enhanced Wound Healing
In Vitro
Wound healing is a complex system involving multiple cell types
and signals with an unknown trigger leading to deregulation and
induction of fibrosis, making it difficult to replicate on the bench.
A simplified in vitro model of wound healing (scratch assay) was
used to determine whether MSCs were having an effect on this
system. The scratch assay was used to examine MSC trophic ef-
fects on primary murine fibroblasts and LA4 cells. The addition
of MSC CM to scratch cultures significantly increased percentage
wound closure at day 3 in both fibroblasts (Figs. 1A and 1B) and
epithelial cells (Figs. 1C and 1D), when compared with wells re-
ceiving control medium. These data demonstrate soluble factors
produced byMSC significantly promotewound closure by epithe-
lial cells and fibroblasts.
HGF is known to enhance lung epithelial cell; CM, conditioned
medium proliferation and is an important soluble mediator re-
leased by MSCs [24]. Lentiviral shRNA techniques were used to
create a stable line of HGF knockdown MSCs (Fig. 2). Character-
ization using surface marker expression (Fig. 2A) and differentia-
tion assays (Figs. 2B and 2C) demonstrated that shHGF MSCs
(shRNA HGF knockdown MSCs) maintain the characteristics of
MSCs. Production of HGF was significantly reduced in shHGF
MSCs but not in nonsilencing control MSCs (Fig. 2D).
To investigate whether MSC CM enhanced wound closure
through thepromotionofmigrationor proliferationof these cells,
3H-thymidinewasadded to thecultures. TheadditionofMSCCMto
scratched fibroblast cultures not only prevented an increase in pro-
liferation but reduced the proliferation to levels significantly lower
than basal division (Fig. 3A). Excessive proliferation of fibroblasts is
a hallmark of fibrosis, and although fibroblasts play a vital role in
wound healing, their accumulation is associatedwith pathogenesis.
Prostaglandin E2 (PGE2) is a key signaling molecule involved in
fibroblasthomeostasis [25–27]and isknowntobesecretedbyMSCs
[28]. To determine the potential role for PGE2 signaling in MSC in-
hibition of fibroblast proliferation, a specific inhibitor of COX-2 (an
Figure 2. shHGFMSCsmaintain the characteristics ofMSCs. HGF knockdownMSCswere tested for (A): surfacemarker expressionofMHCclass
I, MHC class II, Sca-1, CD73, CD105, and CD44 by flow cytometry; (B): Differentiation into bone and fat cells (magnification 3 100); and (C):
Chondrocytes. shHGF MSCs retained the characteristics of MSCs. (D): HGF knockdown MSC conditioned media (CM), nontransduced MSC
CM, and nonsilencing control MSC CM were examined for levels of HGF by enzyme-linked immunosorbent assay. Data are representative
of three experiments for A–C and n = 3 for D. p, p, .05; pp, p, .01. Abbreviations: Chondro, chondrocytes; CM, conditioned medium; Ctrl,
control; HGF, hepatocyte growth factor; MHC, major histocompatibility complex; MSC, mesenchymal stromal cell; Non Sil Ctrl, nonsilencing
control; shHGF, shRNA HGF knockdown.
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enzyme required for the production of PGE2)was added toMSC cul-
tures. Addition of NS-398 to fibroblast scratch assays containing
3H-thymidine significantly prevented MSC CM from inhibiting the
proliferation of fibroblasts (Fig. 3A), whereas knocking down HGF
hadno impact onMSCCMcapacity to inhibit fibroblast proliferation
(Fig. 3A). This data show that PGE2 plays an important role in MSC
inhibition of fibroblast proliferation. The activation of fibroblasts
and differentiation into pathogenic myofibroblasts plays an impor-
tant role in fibrosis [29]. To examine the influence of MSC CM on
fibroblast activation, the expression of a-SMA was examined by
RT-PCR. MSC CM significantly reduced the expression of a-SMA in
fibroblasts following stimulation with TGF-b (Fig. 3B). In contrast
to the suppressive effects on fibroblasts, MSC CM had differential ef-
fects on airway epithelial cells.When culturedwith LA4 cells,MSCCM
significantly increased the proliferation of the epithelial cells (Fig. 3C).
CM collected from MSC was used in culture with LA4 cells to
determine the importance of HGF and PGE2 in MSC CM-induced
proliferation of epithelial cells. Inhibition of the COX-2 pathway
had no impact on MSC CM promotion of epithelial cell prolifera-
tion. Cultureswith HGF knockdownMSC CM showed significantly
lower levels of proliferation comparedwith those containing non-
transduced or nonsilencing control MSC CM (Fig. 3C).
MSC CM Reduction in Epithelial Cell Apoptosis Depends
on HGF Signaling
Following the observation that MSC conditioned media enhanced
in vitro wound healing and epithelial proliferation, further in vitro
work was carried out to examine the potential to inhibit epithelial
apoptosis. Increased epithelial apoptosis is observed alongside the
collagen deposition that results in the significant tissue scarring ob-
served in the lungs during pulmonary fibrosis. Using LA4 epithelial
cells, apoptosiswas induced through the addition of cisplatin (a che-
motherapeutic agent known to induce apoptosis [30]). Cells were
cultured for 24 hours either in media alone or MSC CM. Flow cyto-
metric measurement of annexin V and PI demonstrated that cis-
platin induced LA4 cells to undergo apoptosis. The percentage of
early apoptotic cells (Annexin V+ PI-) (gating strategy shown in Fig.
4A) was significantly reduced with the addition of MSC CM (Figs.
4B and 4C). This demonstrated that the trophic factors produced
by MSCs possess antiapoptotic properties for epithelial cells. To
investigate if this antiapoptotic effect was HGF dependent, HGF
knockdown MSC CM and nonsilencing control CM were added to
the LA4 cells at the same time as cisplatin. The antiapoptotic effect
observed with MSC CM was significantly reduced in LA4 cells cul-
tured with MSC HGF knockdown CM but not the nonsilencing con-
trol CM (Figs. 4B and 4C). These data demonstrate that the soluble
factors produced by MSCs have an antiapoptotic effect on epithelial
cells in vitro and that this effect is largely dependent onHGF signaling.
Early but Not Delayed Administration of MSCs Protects
Against Bleomycin-Induced Lung Fibrosis
To determine whether the positive effects observed with MSC in
vitro translated in vivo, the bleomycinmurinemodel of lung fibrosis
was exploited. A time course study examining a range of fibrotic
and inflammatory genes showed the onset of fibrosis occurs at ap-
proximately day 15, with inflammation beginning 6 days earlier,
Figure 3. MSCs enhance proliferation of LA4 cells and suppress proliferation and differentiation of fibroblasts. (A): Proliferation of fibroblasts
was determined bymeasuring titrated thymidine uptake.MSC CM inhibition of fibroblast proliferationwas negatedwith the addition of 10mM
NS398butnotby thevehicle controlDMSOorbyHGFKDMSCCM. (B):TGF-bdrivendifferentiationof fibroblasts tomyofibroblastswas inhibited
byMSCCM. (C):MSCCMpromotionofLA4proliferationwas lostwhenHGFKDMSCCMwasusedbutNS398hadno impact.n=3.p,p, .05;pp,p, .01.
Abbreviations: CM, conditionedmedia; DMSO, dimethyl sulfoxide; HFG, hepatocyte growth factor; KD, knockdown; LA4,murine alveolar epithelial cell;
MSC, mesenchymal stromal cell; Non Sil Ctrl, nonsilencing control; a-SMA, a smooth muscle actin; TGF-ß, transforming growth factor beta.
1312 MSC to Treat Pulmonary Fibrosis
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
allowing further studies to discriminate between anti-inflammatory
and antifibrotic responses (supplemental online Fig. 1).
This study sought to differentiate between MSCs as an anti-
inflammatory treatment and an antifibrotic therapeutic; there-
fore, administration of MSCs was delayed until the onset of
fibrosis. Based on the results from the time course study, MSCs
were given at day 0 and day 9. Lungs were collected on day 21
for PCR analysis and day 28 for histological examination.
Bleomycin causeda significant increase in collagendeposition
and fibrotic tissue, in comparison with the PBS control lungs (Fig.
5A). TreatmentwithMSConday0 reduced theamountof collagen
detected in the lungs; however, administration of MSCs on day 9
did not demonstrate the same ability to reduce this collagen de-
position (Fig. 5A). The tissue score shows that bleomycin caused
significant fibrotic changes in the lungs. This fibrosis was signifi-
cantly reduced with MSC day 0 treatment. Although MSC day 9
treatment resulted in some reduction in fibrosis, there was a sig-
nificant difference between the two timings of MSC delivery,
again highlighting the differing effects of MSCs administered at
different time points (Fig. 5B). There were also statistically higher
levelsof theproinflammatorycytokine IL-1batday21 inbleomycin-
treated lungs compared with PBS. Consistent with the protective
effect observed in the lung tissue, early administration of MSC
on day 0 but not on day 9 significantly decreased the mRNA ex-
pression of IL-1b in the lungs (Fig. 5C). The protective effect
mediated by early administration of MSCs was associated with
significantly elevated levels of the cytoprotective factor HGF
(Fig. 5D).
HGF Knockdown in MSCs Abrogates the Protective
Effects Observed With Administration at Day 0
Based on our in vitro findings demonstrating the important role
for MSC-derived HGF in the promotion of wound healing and the
correlation between increased HGF expression in vivo and MSC
therapeutic efficacy, we examined the role of HGF inMSC protec-
tion in the bleomycin model.
HGF knockdownMSCsweredirectly comparedwith nonsilenc-
ing controlMSCsandunmanipulatedMSCs in thebleomycinmodel
as described earlier. Trichrome staining indicated that MSCs re-
duced collagen deposition and fibrotic tissue in the lungs (Fig.
6A). HGF knockdown MSCs showed a significantly reduced ability
to protect against the development of fibrosis (Fig. 6A); however,
nonsilencing controlMSCs provided a similar level of protection as
unmanipulated MSCs (Fig. 6A). There was a significant differ-
ence in the fibrotic score in the lung sections between MSCs
and HGF knockdown MSCs (Fig. 6B). This identifies an impor-
tant role of HGF produced by MSCs in early protection against
fibrosis.
EarlyMSCTreatmentReduced LungEpithelial Apoptosis
Induced by Bleomycin In Vivo
Bleomycin induces apoptosis in cells through production of
reactive oxygen species, inducing DNA strand breaks. In vivo,
significant epithelial apoptosis is a predominant feature of
bleomycin-induced fibrosis, contributing to the extensive tissue
damage observed in this model.
To assess whether this protective ability was due to an anti-
apoptotic effect as observed in vitro, a terminal deoxynucleotidyl
transferase (TdT) dUTP nick-end labeling (TUNEL) assay was
performed. Bleomycin exposed lungs displayed high levels of
Figure 4. MSC CM suppresses apoptosis of lung epithelial cells. (A):
Gating strategy; (B): Representative FACS plots; and (C): Quantifica-
tion of apoptosis assay examining the ability of MSC CM to inhibit
alveolar epithelial apoptosis. Apoptosis was measured by double
staining of annexin V and PI and measured by flow cytometry. MSC
CM significantly reduced epithelial apoptosis induced by cisplatin.
This effect was lost when CM from HGF knockdown cells was used.
CM from nonsilencing controls caused no significant difference. Data
are representative of three experiments inB and n = 3 forC. Bar graph
presents the% of early apoptotic cells (lower right quadrant: annexin
V+ PI-) as mean6 standard error of themean. p, p, .05; pp, p, .01.
Abbreviations: CM, conditioned media; HGF, hepatocyte growth fac-
tor; MSC, mesenchymal stromal cell; Non Sil Ctrl, nonsilencing con-
trol; PI, propidium iodide; shHGF, shRNA HGF knockdown.
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apoptosis in comparison with healthy lungs (Fig. 7). This apopto-
sis was reduced following MSC administration, indicated by a de-
creased stain for DNA strand breaks (Fig. 7). HGF has been
implicated in prosurvival and antiapoptotic signaling [20–22] in
the context of fibrosis and other inflammatory disorders. There-
fore, we tested the hypothesis that MSC-derived HGFmediated
the antiapoptotic effect observed in early MSC treatment of
bleomycin in vivo. HGF knockdown MSCs but not nonsilencing
MSCs displayed a decreased ability to inhibit the bleomycin
induced apoptosis, supporting its role in MSC prevention of ap-
optosis (Fig. 7).
DISCUSSION
MSCmanipulation of pulmonary cells was examined in vitro to ex-
plore potential benefits thatmight be exploited in an in vivomodel
of pulmonary fibrosis. The lung is one of the first sites whereMSCs
can be detected after intravenous administration in mice [31].
Figure 5. Early administration ofMSCs protects lungs from bleomycin-induced fibrosis. Lungs were harvested on D28 of the bleomycin model
for histological assessment. (A): Representative images of H&E (upper panel) and trichrome-stained (lower panel) lung sections (103) show
collagen deposition and alveolar damage. Scale bar = 200mm. (B): Fibrotic scorewas significantly reducedwhenMSCswere administered onD0
but not onD9. (C):mRNA expression of IL-1bwasmeasured in the lungs using qPCR on D21 of the bleomycin study. IL-1bmRNA expression was
reduced when MSCs were administered on D0 but not day D9. (D): HGF mRNA expression was measured in the lungs using quantitative po-
lymerase chain reaction. HGFmRNA expressionwas enhancedwhenMSCswere administered onD0 but not onD9. n = 5. p, p, .05; pp, p, .01;
ppp, p, .001. Abbreviations: D, day; H&E, hematoxylin and eosin; HGF, hepatocyte growth factor; IL-1b, interleukin-1b; IN, intranasal; IV, in-
travenous; MSC, mesenchymal stromal cell; PBS, phosphate-buffered saline.
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Some studies in pulmonary diseasemodels suggestMSCsmediate
their effects through engraftment in the lung and differentiation
to alveolar cells, resulting in repair of damaged tissue [11, 12].
Conversely, it has been proposed that MSCs mediate repair
through cell education and trophicmanipulation of themicroenvi-
ronment [9, 32–34]. Given the heterogeneity of in vitro cultured
MSCs, the concepts of regeneration and trophic repair may not
be mutually exclusive [33, 35]. In this study, MSC CM was shown
tohavedynamiceffects pertaining to fibrotic therapy, encouraging
the migration and proliferation of alveolar epithelial cells while
suppressing the activation and proliferation of pulmonary fibro-
blasts. The conditionedmedia also displayed antiapoptotic effects
in lung epithelial cells, where apoptosis was induced through the
addition of the chemotherapeutic drug cisplatin.
Early indications suggested that MSC CM promoted the mi-
gration of both fibroblasts and epithelial cells to the site of dam-
age.However,more in-depth analysis confirmed alternate effects
with MSC CM promoting the proliferation of alveolar epithelial
cells, although fibroblast proliferation was significantly inhibited.
These results demonstrate that MSCs favor the migration and
proliferation of epithelial cells, and although MSCs encourage
the migration of fibroblasts, they also inhibit fibroblast prolifera-
tion and activation. Contrary to these findings, a study by Smith
et al. [36] showed paracrine signaling by MSCs increased the
migration andproliferationof dermal fibroblasts. However, Smith
et al. used dermal fibroblast in their study, which may react dif-
ferently to pulmonary fibroblasts used here: an approach more
relevant to pulmonary fibrosis studies.
Taken together, these results support a role for MSCs in pul-
monary repair and treatment of fibrosis. Fibroblasts play a vital
role inwoundhealing,migrating to the site of damagewhere they
are involved in wound contraction and closure. Here, MSCs were
shown to actively promote fibroblast migration while also con-
trolling the level of proliferation and inhibiting fibroblast activa-
tion. Pathogenesis is associated with the disproportionate
activation of fibroblasts leading to excessive collagen deposition.
This study demonstrates the capacity for MSCs to regulate two
major aspects of fibroblast homeostasis allowing for normal
wound repair. In line with these findings, others have demon-
strated the capacity for MSC CM to control fibroblast activation
through downregulating expression of phosphorylated AKT and
fibronetin [37]. In addition, MSCs promoted both the migration
and proliferation of alveolar epithelial cells, thus consolidating
their potential role in tissue repair by encouraging re- epithelial-
ization. Data from others groups also demonstrate the capacity
for base line MSC CM to support migration and proliferation of
epithelial cell [38, 39]; however, others failed to demonstrate this
effect but showed that MSC CM generated in the presence of
Figure 6. MSC-mediated protection of lungs from bleomycin is dependent of HGF production. Lungs were harvested on D28 of the bleomycin
study for histological assessment. (A): Representative images of H&E (upper panel) and trichrome (lower panel) stained lung sections (1003)
show collagen deposition and alveolar damage. Scale bar = 200mm. (B): Fibrotic score was significantly reducedwhenMSCswere administered
on D0; however, this effect was lost when HGF expression was knocked down in MSCs. n = 5. ppp, p, .001. Abbreviations: D, day; H&E, he-
matoxylin and eosin; HGF, hepatocyte growth factor; MSC, mesenchymal stromal cell; Non Sil Ctrl, nonsilencing control; PBS, phosphate-
buffered saline; shHGF, shRNA HGF knockdown.
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proinflammatory cytokine stimulation (interferon g [IFN-g] and
TNF-a) enhanced epithelial cell migration over and above control
medium [40]. The MSC CM displayed significant antiapoptotic
effects for alveolar epithelial cells mediated in a HGF dependent
manner. Apoptosis of epithelial cells in areas of excessive collagen
deposition contributes to the impaired wound healing and scar-
ring of lung tissue. Similar findings have demonstrated the capac-
ity forMSC CM to protect airway epithelial cells against apoptosis
in vitro buthave failed todefine themechanismof action involved
[41]. The promotion of epithelial migration and proliferation in
conjunction with an antiapoptotic effect in lung epithelial cells
highlights the potential of MSCs as a therapy for the prevention
of fibrosis mediated through their soluble factors.
Data fromanumber of studies on fibroblast proliferation sug-
gested a role for PGE2 [27, 42, 43]. In vitro studies demonstrated
that alveolar epithelial cell inhibition of fibroblast proliferation
wasmediated through PGE2 signaling [27]. Here,MSC production
of PGE2 was blocked using a COX-2 inhibitor (NS398). CM from
NS398-treated MSCs was no longer capable of inhibiting
fibroblast proliferation; however, CMfromHGFknockdownMSCs
maintained capacity to inhibit fibroblast proliferation. These
novel data demonstrate the specificity of this effect mediated
by PGE2 and not HGF and highlights MSC production of PGE2 as
a potential therapeutic candidate in treatment of early fibrosis.
To explore MSC potential in repair of established fibrosis,
the soluble factor responsible for MSC-induced epithelial ex-
pansion was examined. A number of growth factors including
keratinocyte growth factor (KGF), epidermal growth factor
(EGF), and vascular endothelial growth factor (VEGF) have
been implicated in their role in promoting epithelial cell pro-
liferation [44–46].
The presence of KGF in the MSC secretome has been associ-
ated with attenuation of Escherichia coli-induced lung injury [47]
and in ventilator induced lung injury [48]. A partial role has been
identified for VEGF in MSC protection against a cigarette smoke
induced lung injury model [49]. However, HGF is known to play
an important role in the setting of fibrosis and anumberof studies
have investigated the functional capacity of HGF in the context of
promoting epithelial repair in fibrotic lung disease [15, 50, 51]. An
essential role for HGF in MSC-induced proliferation and the anti-
apoptotic protection of epithelial cells was demonstrated here
using conditionedmedium fromHGF knockdown cells. Similar re-
sults were observed in fetal intestinal epithelial cells where HGF
secreted by MSCs enhanced their viability and proliferation [52].
Recently, in another model of lung disease, we have demon-
strated thatMSC CM is less efficacious thanMSCs and this is likely
associated with the capacity for MSC to continually secrete tro-
phic factors such as HGF (Kennelly et al., manuscript in prepara-
tion). Therefore, the capacity for MSCs to protect against fibrotic
disease and themechanismof action involvedwas investigated in
the bleomycin model.
Bleomycin is a resolving model of pathogenesis [53], and al-
though it has drawbacks in that it does not recapitulate all aspects
of the humandisease, it is themodelmost often used to test ther-
apeutic efficacy in idiopathic pulmonary fibrosis. The model is
nowknown to divide into twodistinct phases: an initial inflamma-
tory phase brought about by immune cell infiltration to the site of
damage, followed by a fibrotic phase resulting from fibroblast re-
cruitment and proliferation [54]. The timing of administration of
potential therapeutics is essential for distinguishing betweenpre-
ventative anti-inflammatory therapy and antifibrotic therapy.
Based on this observation, we chose to examine the therapeutic
efficacy ofMSC administered early on day 0 or late on day 9when
the fibrotic phase had been initiated.
The in vivo model of fibrosis demonstrated that early ad-
ministration of allogeneic MSCs protected the lung architecture
from bleomycin-induced damage. Early MSC administration sig-
nificantly reduced fibrosis, apoptosis, and the production of the
proinflammatory cytokine IL-1b in the lungs. A study carried out
by Lan et al. [37] demonstrated similar outcomes with reduced
fibrotic score and decreased IL-1b and IL-6 in a bleomycin model
following MSC administration on day 3. The beneficial effects of
MSC-derived HGF observed in vitro (in terms of wound healing
and apoptosis) were recapitulated in vivo with significant increases
in HGF detected in lungs of mice receiving early administration of
MSCs. Moreover, other studies have demonstrated elevated levels
of HGF and decreased apoptosis in the lung followingMSC adminis-
tration, [37, 55] supporting these findings.
In contrast, delayedMSC dosing failed to protect, resulting in
significantly higher pathological scoring, nodecrease in IL-1b, and
Figure 7. MSC-mediated protection of lungs from bleomycin through
reduction of apoptosis in an HGF-dependent manner. TUNEL analysis
was carried out on lung sections to demonstrate that bleomycin induced
apoptosis in the lungs, although MSC treatment reduced this. However,
this antiapoptotic effect was lost when mice were treated with HGF KD
MSCs,demonstrating thatMSCs requireHGFtoprotectagainstapoptosis.
Tissue was counter-stained with DAPI. Representative images from n = 5
mice per group. Scale bars = 50mm. Abbreviations: DAPI, 49,6-diamidino-
2-phenylindole; HGF, hepatocyte growth factor;MSC,mesenchymal stro-
mal cell;NonSilCtrl,nonsilencingcontrol;PBS,phosphate-bufferedsaline;
shHGFMSC, shRNAHGF knockdownMSC; TUNEL, terminal deoxynucleo-
tidyl transferase dUTP nick-end labeling.
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no increase inHGFwhen comparedwith theMSCday 0 treatment
group. Our findings are in line with other studies [11, 56] demon-
strating that protective effects were observed only from MSCs
administered directly after bleomycin challenge and not at day
9 after fibrotic disease has been initiated.
Administration of therapeutics at day 0 is common practice in
bleomycin animal models and reports have claimed beneficial
results from MSCs under these conditions [12, 13, 57]. Early ad-
ministration of MSCs reduced pathology but not by ameliorat-
ing direct fibrosis. Delayed administration had no effect on
reducing established fibrosis and was not as effective at reduc-
ing inflammation. These results have important implications
on future therapeutic candidate studies, with the success of
potential antifibrotic therapies being determined by their
efficacy following delayed administration in the bleomycin
model.
Many studies have shown the capacity for MSCs to protect
against bleomycin-induced lung fibrosis [12, 13, 37, 57, 58]. These
studies have implicated a range of mechanisms of action including
reduction of IL-1 and TNF-a by IL-1 receptor antagonist [13], amelio-
ration of oxidative stress, endoplasmic reticulum stress, and TGF-b1
production in alveolar epithelial cells in a staniocalcin-1 dependent
mechanism [58]. Evidence from the literature supports a protective
role forHGF in fibrotic lungdisease.Apoptotic cellshavebeenshown
tomodulate bleomycin lung fibrosis through the production of HGF
alone [59] or in combinationwith PGE2 [60]. Notably, a recent study
has identified the role for a secreted factor inMSCprotectionagainst
lung fibrosis and acute lung injury using conditioned medium from
amnioticmembrane derived cells [61] or proinflammatory cytokine-
activated MSCs [62]. Similar observations have been made in other
cells types including induced pluripotent stem cells, with reduced
lung fibrosis mediated in part by HGF [63]. In line with this, hypoxia
preconditioning or overexpression of HGF in MSCs leads to better
efficacy of MSCs in preventing lung fibrosis and this was associated
with increased levels ofHGF [37, 64].Given thepartial role identified
forHGF inMSCprotectionagainstbleomycin-induced lung fibrosis, it
is plausible that other secreted factors such as PGE2 might play a
complementary role.
CONCLUSION
Our study is the first study to definitively show the importance of
(naturally derived) HGF in MSC protection in the bleomycin model
in providing clear mechanistic studies translating in vitro finding
to a preclinical model of bleomycin-induced fibrosis. Moreover,
the data herein support the theory that MSCs have cytoprotec-
tive properties and highlight the important role of MSCs in the
repair process through prevention of apoptosis, suppression of
fibroblast proliferation, and promotion of epithelial cell prolif-
eration. In vivo, the protective effect of MSCs may have far-
reaching clinical applications but will depend on the accuracy
of timing in administration.
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